# OnCo record neutropenia (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/neutropenia/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "neutropenia" ;
  schema:name "Neutropenia"@en ;
  schema:alternateName "neutropenic"@en, "neutropaenia"@en, "low neutrophils"@en, "neutrophil count"@en, "absolute neutrophil count"@en, "ANC"@en, "grade 4 neutropenia"@en, "grade 3-4 neutropenia"@en, "prolonged neutropenia"@en, "nadir"@en, "count nadir"@en, "leukopenia"@en, "leucopenia"@en, "white cell count"@en, "agranulocytosis"@en ;
  schema:description "A shortage of neutrophils, the white blood cells that fight bacteria, caused by chemotherapy hitting the bone marrow. It usually bottoms out (the nadir) 7-14 days after each cycle and recovers before the next; while low, infection risk is high."@en ;
  schema:url <https://onco.cc/terms/neutropenia/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neutropenia> ;
  schema:citation <https://en.wikipedia.org/wiki/Neutropenia>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/sepsis>, <https://www.nice.org.uk/guidance/cg151>, <https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/sacituzumab-govitecan-trodelvy>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/folfirinox>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/nab-paclitaxel>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/folfox>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/irinotecan>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/growth-factors> ;
  onco:related <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/cytopenias/>, <https://onco.cc/terms/thrombocytopenia/>, <https://onco.cc/terms/dose-modification/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/splenic-marginal-zone-lymphoma/>, <https://onco.cc/cancers/nodal-marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/angioimmunoblastic-t-cell-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/sezary-syndrome/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/g-csf-growth-factors/> .